What stage is it at?
Nurevo is at pre-seed stage. There is a working prototype of the data pipeline, and Nurevo is preparing clinical validation.
Straight answers on what Nurevo does, who it is for, how data is handled, and how to get in touch.
Nurevo is at pre-seed stage. There is a working prototype of the data pipeline, and Nurevo is preparing clinical validation.
No. Nurevo is a screening and triage tool. It is not a diagnostic device.
A short guided conversation on a phone or laptop is analysed across speech, language and facial signals, together with background information, to produce an explainable risk score.
Nurevo is designed for diverse, multilingual populations. Screening is not built around one language or culture.
Not yet. Nurevo is in development and is not currently available for clinical use.
Not yet. Nurevo is at prototype stage and is preparing clinical validation. No performance figures are published.
Not at present. Nurevo holds no conformity marking and no regulatory clearance. Nurevo intends to follow the UK pathway for software as a medical device, overseen by the MHRA.
We welcome conversations about future pilots and research. Nurevo is not yet available for clinical use. Use the clinical and research partners route on the contact page.
Nurevo is for health systems and memory services, for primary care, for care homes and community organisations, and for pharmaceutical companies and contract research organisations.
Nurevo designs for consent, UK GDPR and data minimisation. Please do not include personal health information in messages sent through this website.
The storage region has not been published. The service is being designed around consent, UK GDPR and data minimisation.
Nurevo is being designed to support recruitment and stratification for early-stage trials. It is in development and not yet available for use in trials. Use the clinical and research partners route on the contact page.
No. The conversation is designed for everyday devices: a phone or a laptop.
Nurevo builds AI cognitive screening that turns a short, natural conversation into an explainable risk score for cognitive decline, helping clinicians decide who needs specialist assessment first. In plain terms, Nurevo is building this screening for dementia.
Nurevo is multimodal rather than single-signal, built for multilingual populations from the start, and explainable by design. It is low-burden and conversational.
Nurevo is headquartered in Edinburgh, United Kingdom. The team is based in the UK, with team members internationally. Nurevo Technology Limited is registered in Scotland, company number SC892389. The registered office is 89/63 Holyrood Road, Edinburgh, EH8 8BA, United Kingdom.
Use the contact page, or email info@nurevo.tech. Investment, clinical, research and media messages all go to that address.
Not at the moment. Nurevo is in development and is not available for clinical or personal use. If you are worried about your memory, speak to your GP.
Last updated